-
New target DDR1: a "double-edged sword" for solid tumors
Time of Update: 2022-12-30
Global drug discovery for DDR1Table 2: Development of antibodies targeting DDR1With the rapid development of artificial intelligence and deep learning, more and more DDR1 kinase inhibitors have been rapidly identified, which will greatly promote DDR1 kinase inhibitors to play a greater role in solid tumors.
-
Express significantly improves progression-free survival of advanced gastric cancer! Potential "first-in-class" therapies show impressive Phase 3 clinical data
Time of Update: 2022-12-30
2), in combination with chemotherapy, has met its primary endpoint in a Phase 3 clinical trial for the first-line treatment of patients with locally advanced unresectable or metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, significantly prolonging progression-free survival (PFS).
-
Medication recommendations and personal protection for new coronary pneumonia in cancer patients
Time of Update: 2022-12-30
1On December 7, 2022, the Comprehensive Group of the Joint Prevention and Control Mechanism of the State Council to Respond to the Novel Coronavirus Pneumonia Epidemic recommended common drugs for home treatment of people infected with the new coronavirus infection, as shown in the following figure2Drug introduction - list of commonly used drugs for symptomatic treatmentTumors belong to the scope of underlying diseases, and tumor patients often have low immunity and liver and kidney dysfunction due to chemotherapy and immunotherapy.
-
Phase III NSCLC immunotherapy drug inventory, come and see which drugs can be used
Time of Update: 2022-12-30
IMpower010 study: In PD-L1 TC≥1% of patients, adjuvant atezolizumab has brought OS benefit trend In recent years, immunotherapy has also made many breakthroughs in the perioperative treatment of NSCLC 。 In March 2022, the Chinese NMPA officially approved atezolizumab monotherapy for the adjuvant therapy of patients with stage II-IIIA NSCLC who were evaluated as ≥1% of tumor cells (TC) PD-L1 stain-positive, surgically resected, and followed by platinum-based chemotherapy.
-
CUA 2022| Professor Huang Jian: Precise targeting + combination therapy, the future battle of bladder cancer should be fought like this
Time of Update: 2022-12-30
Professor Huang Jian mentioned that immunotherapy + chemotherapy has become a popular choice for the treatment of bladder cancer, and has good results in advanced bladder cancer treatment, maintenance therapy, and neoadjuvant therapy, and many studies of immune + targeted therapy are underway, including PD-1/PD-L1 inhibitor + ADC, PD-1/PD-L1 inhibitor + RTK inhibitor, PD-1/PD-L1 inhibitor + FGFR inhibitor and so on.
-
Immunotherapy for the treatment of hematological tumors
Time of Update: 2022-12-30
What are the successful immunotherapy regimens for hematological cancers?Five immunotherapies have been successful in the treatment of hematologic malignancies (Figure 1): allogeneic hematopoietic stem cell transplantation; monoclonal antibodies and innovatively designed ADCs and bispecific T-cell engager; Targeting B cells: immunomodulatory small molecules; Immune checkpoint inhibitors; CAR T-cell therapy.
-
Directly cool the tumor! Their growth can be greatly restricted
Time of Update: 2022-12-30
▲ The study envisaged a concept of a cryogenic device installed in the human body (Image source: Reference [1]) Throughout the experiment, rats carrying the device successfully survived, and their survival time was about twice as long.
-
Maximum diameter 12 cm! Beijing Boai Hospital successfully treated patients with huge intracranial tumors
Time of Update: 2022-12-30
(Chen Yawen/Photo) (Operator: Jing Xuetao) "I sincerely thank you for giving me a second life, without your responsibility and superb medical skills, I would not be where I am today!"On the morning of December 4, a young woman in Beijing who had suffered from a giant intracranial meningioma (pseudonym) was discharged after full treatment by the neurosurgical staff of Beijing Boai Hospital of the China Rehabilitation Research Center.
-
【Cancer Cell】New! The Weill Cornell team identified potential treatments for metastatic colon cancer
Time of Update: 2022-12-30
This article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by SophiaMesenchymal colorectal cancer (mCRC) is microsatellite-stable (MSS), highly connective tissue hyperplasia, CD8 T cells are excluded from the peristromal periphery, resistant to immunotherapy, and driven by low levels of atypical protein kinase Cs (aPKC) in the intestinal epithelium.
-
Why can I suddenly learn that I have advanced lung cancer and gain survival for more than 3 years?
Time of Update: 2022-12-30
During the treatment, the doctor also often gave me encouragement, informed me of the situation in time, everything was relatively smooth, and I saw that the patients in the same ward were optimistic and positive, chemotherapy, taking medicine, chatting, walking, life continued as usual, as if lung cancer is not so terrible.
-
Professor Zhang Li's team: The research results of multi-day chemotherapy antiemetic were published in the Lancet sub-journal
Time of Update: 2022-12-30
prefaceOn December 15, a team led by Professor Zhang Li of the Department of Internal Medicine of the Cancer Center of Sun Yat-sen University published an article entitled "Multicenter, double-blind randomized controlled phase 3 clinical trial of olanzapine combined with triple antiemetic regimen for the prevention of nausea and vomiting caused by multi-day chemotherapy of highly emetogenic drugs" in the Lancet sub-journal eClinicalMedicine (impact factor = 17.
-
Make up for the gap at home and abroad! Sun Yat-sen University's new chemotherapy regimen significantly reduces the risk of liver cancer recurrence!
Time of Update: 2022-12-30
This study is the first in the world to confirm that adjuvant FOLFOX hepatic artery perfusion chemotherapy can reduce the risk of postoperative recurrence in people with liver cancer complicated with microvascular invasion, and has good safety, filling the gap in this field at home and abroad.
-
2022 SABCS East Wind is Coming Today, Green Lake Up the Mountain - New Dynamics of CDK4/6 Inhibitors in HR+/HER2-Breast Cancer!
Time of Update: 2022-12-30
Featured Study IV (P5-02-02)Relationship between ER+/HER2-metastatic breast cancer genome mapping and previous CDK4/6i treatmentTo understand the molecular processes driving CDK4/6i resistance, the researchers genetically tested 1,853 patients with ER+/HR2 advanced breast cancer and found that patients who had previously received treatment showed significant ESR1 mutation rates in solid tissue and liquid biopsies compared with patients who did not receive CDK4/6i.
-
Grasp accurately, standardize first, optimize the management of adverse reactions in the first-line treatment of EGFR-TKI in the third generation, and standardize the application of clinical practice
Time of Update: 2022-12-30
Three generations of EGFR-TKI-associated oral mucositis management measuresDose adjustment and discontinuation principle of EGFR-TKI in three generations(1) Dose adjustment and discontinuation principle of osimertinibOsimertinib should be adjusted or permanently discontinued in patients presenting with interstitial lung disease (ILD)/noninfectious pneumonia, abnormal electrocardiograms, life-threatening arrhythmias or symptomatic heart failure, Stevens-Johnson syndrome (SJS), erythema multiforme majors (EMM), aplastic anemia, or other adverse effects (Table 1).
-
Inventory of 2022 Professor Shen Lin: Progress in gastric cancer treatment in 2022
Time of Update: 2022-12-30
About the authorProfessor Shen LinBeijing scholar, chief physician, professor, doctoral supervisor. Former Vice President of Peking University Cancer Hospital and former Deputy Director of Beijing Can
-
Medical interview Liu Zhenzhen: Immunotherapy for early triple-negative breast cancer is gradually getting better
Time of Update: 2022-12-04
Recently, the State Food and Drug Administration also approved pembrolizumab in combination with chemotherapy for neoadjuvant therapy in patients with early-stage high-risk triple-negative breast cancer (TNBC) who express PD-L1 (comprehensive positive score (CPS) ≥20) with well-validated tests.
-
Have the most common cancer in the world and are afraid that chemotherapy will be toxic to the heart? Might as well try this method
Time of Update: 2022-12-04
Image source: 123RFIn the study, 104 female participants with early-stage (stage 1-3) breast cancer who planned to receive chemotherapy were randomly divided into two groups:Control group: only usual care after chemotherapy; Test group: In addition to receiving routine care after chemotherapy, aerobic exercise or resistance exercise is performed 3-4 days a week under the guidance of medical staff.
-
Gamida's HER2 CAR-NK therapy was presented at the SITC conference, and the tumor suppression based on NAM platform technology was significant
Time of Update: 2022-12-04
544px;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;margin-bottom: 0px;">——List of recent popular events——On November 16, a new choice of cationic liposomal mRNA delivery vehicle was createdTo this end, Gamida Cell, a NAM engineered cell therapy development company, has developed a proprietary NAM (nicotinamide) platform for in vitro expansion of allogeneic NK cells, enhancing NK cell function by preventing cell failure, improving cytotoxic activity, producing protection against oxidative stress, and exhibiting better homing to lymphoid tissue.
-
New advances in ADC therapy for HER2-positive breast cancer brain metastases
Time of Update: 2022-12-04
IN THE PATRICIA STUDY, HIGH-DOSE PH DUAL-TARGETED THERAPY HAD A CERTAIN EFFICACY ON BREAST CANCER BRAIN METASTASIS, WITH A CNS ORR OF 11%, A CLINICAL BENEFIT RATE OF 68% AT 4 MONTHS, AND A CLINICAL BENEFIT RATE OF 51% AT 6 MONTHSSmall molecule TKI is a commonly used anti-HER2 therapeutic drug in clinical practice, and the activity of TKI in the treatment of brain metastases has also been explored in a number of clinical studies [5].
-
Effect of hematopoietic stem cell transplantation on the long-term prognosis of CD30+ PTCL patients receiving vebutuximab in combination with CHP first-line
Time of Update: 2022-12-04
The randomized, double-blind phase 3 ECHELON-2 study (NCT01777152) showed that first-line vebutuximab combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) significantly improved progression-free survival (PFS), overall survival (OS), complete response (CR), and overall response rate (ORR) in patients with CD30+ PTCL compared with traditional CHOP regimens, with 。 As first-line therapy improves, the role of HSCT consolidation therapy also needs to be reassessed.
